Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice

Rabia Agca,Yvo Smulders,Michael Nurmohamed
DOI: https://doi.org/10.1136/heartjnl-2019-316378
IF: 5.7
2021-03-04
Heart
Abstract:Learning objectives To create awareness of the increased cardiovascular disease risk in immune-mediated inflammatory diseases. To understand the aetiology of increased cardiovascular disease risk in immune-mediated inflammatory diseases, in particular the independent roles of traditional cardiovascular risk factors and chronic inflammation. To realise the importance of treatment of both cardiovascular risk factors as well as optimal anti-inflammatory therapy to reduce cardiovascular disease risk. Introduction Immune-mediated inflammatory diseases (IMIDs) comprise a wide range of conditions of which rheumatoid arthritis (RA), spondyloarthritis (SpA) and inflammatory bowel disease (IBD; ie, Crohn's disease and ulcerative colitis) are most common (table 1, table 2). SpA consists of a range of diseases, including ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis, spondylitis associated with IBD and undifferentiated SpA.1 As data regarding cardiovascular disease (CVD) risk are mainly available for RA, AS, PsA,...
cardiac & cardiovascular systems
What problem does this paper attempt to address?